{"id":"W3046033709","doi":"10.1177/2047487320941987","title":"Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial","year":2020,"lang":"en","type":"article","venue":"European Journal of Preventive Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"Genentech; Esperion Therapeutics; Sirtex Medical; Servier; Eisai; Medicines Company; Amarin Corporation; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; European Society of Cardiology; American Regent; Sanofi; Amgen; Pfizer","keywords":"Alirocumab; Medicine; Statin; Internal medicine; Hazard ratio; PCSK9; Acute coronary syndrome; Adverse effect; Placebo; Myocardial infarction; Cardiology; Cholesterol; Confidence interval; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00340884,0.0006192137,0.001728076,0.0002204613,0.0002800564,0.0009013806,0.0004804401,0.0005744077,0.001233472],"category_scores_gemma":[0.004457463,0.0002168484,0.001464212,0.0004389175,0.0004369783,0.0005724778,0.0008044526,0.001093775,0.00009515187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005021928,"about_ca_system_score_gemma":0.0005309269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001580809,"about_ca_topic_score_gemma":0.003275793,"domain_scores_codex":[0.9984065,0.0009003073,0.0001402354,0.0002135502,0.000199268,0.0001402639],"domain_scores_gemma":[0.9974841,0.0006926942,0.001037676,0.00023191,0.0001474561,0.0004060846],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6856344,0.002349899,0.2319546,0.001212012,0.01648295,0.00008862762,0.0002433627,0.001047399,0.002335366,0.0004364497,0.002077633,0.05613734],"study_design_scores_gemma":[0.1752632,0.02111415,0.7813686,0.0003620547,0.01385796,0.000202127,0.0002052766,0.002351795,0.0007157717,0.001196942,0.003264712,0.00009739434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901862,0.007062329,0.0002302912,0.0004996784,0.00005792296,0.0001164136,0.0006736229,0.00001153187,0.001161928],"genre_scores_gemma":[0.9960009,0.001501992,0.0004927788,0.0004337026,0.0001639665,0.0001445036,0.0009755029,0.000005735367,0.0002808992],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00340884,"threshold_uncertainty_score":0.01802784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02869394666617581,"score_gpt":0.2715843761862793,"score_spread":0.2428904295201035,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}